| Revenue growth | 42% YoY growth in FY26; FY27 target ₹380cr. |
|---|---|
| Margins | EBITDA margins improved to 37% in Q4 due to efficiency. |
| Order book | Over 60 oncology contracts signed; 35+ discussions ongoing. |
| Demand visibility | Strong export pipeline with 300+ dossiers and 60+ business contracts. |
| Management confidence | High; citing revenue-generating oncology setup and regulatory milestones. |
Growth
FY26 revenue reached ₹251.7cr (+42% YoY); PAT surged 74% to ₹30.5cr. Oncology now contributes 38% of revenue.
Outlook
Guided ₹380cr revenue for FY27; oncology revenue target of ₹200cr. Long-term aspiration of ₹800-1,000cr at optimal utilization.
Risks
Regulatory approval timelines for dossiers; logistics disruptions and indirect impacts from Middle East conflicts.
Earnings Call filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,028.80
- Market cap
- ₹2,289 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 63.4×Sector 47.4×
- Promoter holding
- 52.52%-0.34% QoQ
- FII holding
- 12.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare Annual General Meeting
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Regulatory Approval
Sakar Healthcare Limited received 14 oncology product approvals in the EU, UK, and Canada. These approvals for licensed-out products and site variations will drive top-line sales growth.
Sakar Healthcare Annual General Meeting
Sakar Healthcare Limited submitted its 22nd Annual General Meeting notice and the Annual Report for FY 2025-26. The meeting is scheduled for September 22, 2026.
Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
- Call
- Guides 100% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.